Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19390314 | 1.00 | DPP4 (0.47) | DPP4SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL7029573 | 0.83 | L3MBTL1 (0.60) | DPP4SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL22397770 | 0.79 | POLB (0.52) | SMN1; SMN2KMT2AMEN1NPSR1L3MBTL1 | |
| SCHEMBL13327274 | 0.79 | POLB (0.52) | SMN1; SMN2KMT2AMEN1NPSR1L3MBTL1 | |
| SCHEMBL4676752 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL10059185 | 0.78 | DPP7 (0.51) | DPP4SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL19390302 | 0.78 | DPP7 (0.51) | DPP4SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL3219970 | 0.77 | FABP5 (0.49) | SMN1; SMN2NPC1RAB9ACACNA1GKMT2A | |
| SCHEMBL10059188 | 0.76 | MEN1 (0.61) | DPP4SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19390153 | 0.76 | MEN1 (0.61) | DPP4SMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655399-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012083436-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | F2, F12, SERPINC1 | DPP4 895/4885SMN1; SMN2 2988/4885CYP2C19 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.